Shareholder Protection Insurance

The shares form part of the estate and pass under the will, or under the intestacy rules if none exists. In most owner-managed companies that means a surviving spouse or adult children, none of whom may want any involvement.

From there, several unhappy outcomes are common. The beneficiaries may want to be paid out and the company simply cannot fund it. They may keep the shares and expect dividends the business needs to reinvest. They may want to sell to a third party — occasionally a competitor. Or they may want an active role the other owners do not want them to have.

The company’s articles may contain pre-emption rights giving existing shareholders first refusal, which helps a little. But pre-emption gives you the right to buy, not the money to buy with, and a right you cannot fund is of limited use.

Meanwhile the family’s position is genuinely difficult. They hold a minority stake in a private company with no ready market, often no income from it, and potentially an inheritance tax bill on a valuation they cannot realise. That combination is what turns a bereavement into a dispute.

This distinction is the most consequential technical point on the page, and it is where arrangements most often go wrong.

A buy-and-sell agreement obliges the survivors to buy and the estate to sell. It is a binding contract for sale, and that is the problem: HMRC’s position is that a binding obligation to sell means the deceased no longer held qualifying business property outright at death — they held a right to proceeds. Business Property Relief can be lost as a result.

A cross-option agreement gives each party an option rather than an obligation. Because neither side is contractually bound to transact until an option is exercised, the shares remain qualifying business property at the date of death, and BPR is preserved. In practice the outcome is the same — either party can force the transaction — but the tax treatment is entirely different.

The difference is not cosmetic. On a substantial shareholding, losing BPR can turn a modest inheritance tax liability into a seven-figure one.

If you already have shareholder protection in place, find out which structure your agreement uses. Older arrangements, and arrangements set up without specialist input, are frequently drafted as buy-and-sell.

Substantially, and a lot of the advice online has not caught up.

Until 5 April 2026, qualifying business property attracted unlimited 100% relief, so most owner-managers could assume their shares passed free of inheritance tax. From 6 April 2026, 100% relief applies to the first £2.5 million of combined qualifying business and agricultural property per person, with 50% relief on the excess — an effective 20% rate above the allowance rather than full exemption. Unused allowance is generally transferable between spouses and civil partners, and inheritance tax on qualifying assets can be paid in ten equal annual instalments, interest free.

Note the history, because it causes confusion: the cap was announced at £1 million in the Autumn Budget 2024 and raised to £2.5 million before commencement. Material still quoting £1 million is out of date.

Two consequences follow. First, preserving BPR now matters more, not less, which makes cross-option drafting critical. Second, owners of larger businesses may face a real inheritance tax liability where none was expected, and that liability needs its own planning — separate from, and alongside, the shareholder protection arrangement.

Valuing a private company is genuinely difficult, and there is no single correct method. Common approaches include a multiple of maintainable earnings, net asset value, or a formula agreed between the owners and written into the shareholders’ agreement.

Two practical points matter more than the method chosen.

The first is minority discounts. A 20% holding is not usually worth 20% of the company, because a minority stake carries no control. If the cover is set on a straight pro-rata basis it may overshoot; if the agreement applies a discount the estate did not expect, it causes friction at the worst possible time. Agree the basis in advance and put it in writing.

The second is drift. Businesses grow, and a sum insured set five years ago is often badly out of date. Some policies offer increasing cover or a guaranteed insurability option allowing you to raise the sum without further underwriting on defined events.

Whatever basis you choose, review it annually alongside the accounts. Your accountant should be involved in the valuation, and we are happy to work alongside them.

Both routes exist and they are treated differently.

Where individual shareholders pay from personal funds, there is no corporation tax relief and no benefit in kind. The proceeds are normally paid free of tax to the trustees and on to the surviving shareholders. This is the more common structure for a cross-option arrangement, and it is usually the cleaner one.

Where the company pays the premiums on policies benefiting the shareholders personally, HMRC will generally treat this as a benefit in kind assessable on each shareholder, with the company potentially getting a corporation tax deduction but also facing Class 1A National Insurance. Some owners equalise the position with adjustments between shareholders where holdings or ages differ materially.

There is also a company purchase of own shares route, where the company itself buys the shares back rather than the individuals. It has its own conditions under the Companies Act — distributable reserves, procedural requirements — and different tax consequences for the seller. It suits some businesses and not others.

None of this is one-size-fits-all, and the right answer depends on the company’s structure, reserves and the shareholders’ personal positions. It should be decided with your accountant.

Death is the risk everyone thinks of, but a shareholder surviving a serious illness and being unable to return can be harder for a business to absorb.

Adding critical illness cover means an option can be triggered on diagnosis of a specified condition, allowing the shares to be bought while the shareholder is still alive. It costs meaningfully more than life-only cover, and it introduces a consideration worth thinking through carefully: if the agreement makes the critical illness option exercisable by the other owners, they could in principle compel you to sell your shares following a diagnosis, whether or not you wish to go.

Many arrangements handle this with a single option on critical illness — the ill shareholder can require the others to buy, but they cannot force a sale on them — while retaining the full double option on death. That protects the person who is unwell without stripping them of choice.

It is a decision about how the owners want to treat each other, not just a pricing question. We would rather talk it through properly than default to whichever is cheaper.

The principle transfers directly. Partnership and LLP protection works the same way — policies on each partner or member, held under trust, supported by an option agreement drafted to match the partnership agreement or LLP members’ agreement rather than company articles. The terminology changes; the mechanics do not.

Key person insurance is a different thing entirely, and the two are frequently confused. Key person cover protects the company against the loss of someone whose skills, relationships or expertise drive profit — a lead salesperson, a technical director, a founder. The company owns the policy, pays the premiums and receives the proceeds, using them to cover lost profit and the cost of recruiting a replacement.

Shareholder protection protects the ownership, funding the transfer of shares between individuals.

A founder-director is often both: key to trading performance and a significant shareholder. Losing them creates two distinct financial problems, and one policy will not solve both. Many owner-managed businesses need both arrangements, and it is worth mapping the whole picture at once rather than in pieces.